September Issue of Patient Care Online Supplement is Now Live

Death Rates from Obesity-Related Heart Disease Soared Nearly 200% Between 1990 and 2020, Researchers Report

News

Article

Find details on advances in the management of type 1 diabetes, utilization of CGM in primary care settings, and optimizing T2D management in older persons.

The latest issue of the Patient Care Online digital supplement is now live. This month’s supplement focuses on screening, treatment, and management of diabetes. Topics include navigating treatments to delay the progression to type 1 diabetes, the utilization of continuous glucose monitoring in the primary care setting, and the challenges of ensuring safe and effective care for older adults with type 2 diabetes.

Patient Care Online September 2024 Supplement

Find out more in the supplement, here.

Related Content

November 11th 2024

Obesity & Type 2 Diabetes: An Expert Discussion

AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.

June 30th 2023

New Phase 3 Trials Investigate Survodutide as a Promising Treatment for Obesity

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

November 6th 2024

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.

July 22nd 2022

Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

November 5th 2024

ObesityWeek 2024: Viking Therapeutics Presents New Positive Data from VK2735 Obesity Program

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

November 4th 2024

Death Rates from Obesity-Related Heart Disease Soared Nearly 200% Between 1990 and 2020, Researchers Report

Results from the VENTURE phase 2 trial and a phase I oral formulation study found that VK2735, a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.

Related Content

November 11th 2024

Obesity & Type 2 Diabetes: An Expert Discussion

AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.

June 30th 2023

New Phase 3 Trials Investigate Survodutide as a Promising Treatment for Obesity

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

November 6th 2024

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

SYNCHRONIZE-1 and -2 will provide "robust evidence" on the safety, efficacy, and tolerability of survodutide in adults with obesity with or without T2D.

July 22nd 2022

Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

November 5th 2024

ObesityWeek 2024: Viking Therapeutics Presents New Positive Data from VK2735 Obesity Program

ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.

November 4th 2024